Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 04 - 30 save search
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-04-30 (Crawled : 22:00) - biospace.com/
SRPT | $117.885 0.51% 0.48% 550K
|
Health Technology
|
| O: -0.43%
H: 1.54%
C: -0.37%
treatment duchenne
Worldwide Dry Eye Disease (DED) Industry to 2026 - by Disease, Treatment, End-user, Distribution Channel and Region
Published: 2021-04-30 (Crawled : 20:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% 0.22% 7.9M
|
Health Technology
| Email alert
Add to watchlist
dry eye disease treatment eye eye disease distribution
Global Allergy Treatment Markets, 2020-2021 & Forecast to 2028: Increasing Adoption of Immunotherapy in Allergy Treatment & Developments in Food Allergy Treatments
Published: 2021-04-30 (Crawled : 19:00) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
food treatment immunotherapy therapy
Worldwide Neurological Diseases Treatment Industry to 2029 - Featuring Novartis, GlaxoSmithKline and Bayer Among Others
Published: 2021-04-30 (Crawled : 16:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.48%
H: 0.57%
C: -0.44%
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
|
| O: 0.61%
H: 0.4%
C: -1.03%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: 3.7%
H: 2.42%
C: -0.38%
disease treatment neurological
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEEPRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022
Published: 2021-04-30 (Crawled : 14:00) - biospace.com/
PRAX | $50.78 -3.11% -3.6% 270K
|
Health Technology
|
| O: -2.42%
H: 1.4%
C: -2.48%
treatment phase 2 drug trial designation
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
Published: 2021-04-30 (Crawled : 14:00) - biospace.com/
LNTH | $61.48 -0.41% -0.39% 540K
|
Health Technology
|
| O: -1.06%
H: 2.28%
C: 1.85%
treatment gene therapy therapy gene therapies
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
Published: 2021-04-30 (Crawled : 13:15) - globenewswire.com
PRAX | $50.78 -3.11% -3.6% 270K
|
Health Technology
|
| O: -2.42%
H: 1.4%
C: -2.48%
treatment drug designation
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
LEGN | $48.83 -2.57% -2.62% 1.4M
|
Health Technology
|
| O: -0.37%
H: 0.8%
C: 0.33%
treatment europe therapy car-t biotech iot submission cel
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% 0.82% 9.9M
|
Health Technology
|
| O: -1.42%
H: 1.23%
C: 0.68%
food treatment drug application nivolumab urothelial carcinoma
Analyzing COVID-19 Impact on Fracking Water Treatment Market | $ 1.12 Billion Growth Expected During 2021-2025 | Technavio
Published: 2021-04-30 (Crawled : 08:00) - prnewswire.com
XYL | $126.22 -1.39% 0.0% 1.4M
|
Producer Manufacturing
|
| O: -0.69%
H: 0.39%
C: -0.75%
covid treatment growth
Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Published: 2021-04-29 (Crawled : 02:00) - globenewswire.com
ELOX | $0.9625 -2.52% -51.57% 93K
|
Health Technology
|
| O: -1.4%
H: 3.77%
C: 2.83%
treatment phase 2 ongoing fibrosis cystic fibrosis
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.